Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lithium Americas Corp (LAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lithium Americas Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Lithium Americas Corp trades at $3.3 (market cap $1.16B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 34.4× Lithium Americas Corp's market cap. Which is the better fit depends on your goals.
| ALNY | LAC | |
|---|---|---|
Market Cap | $39.89B | $1.16B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $10.05 |
52-Week Low | $278.09 | $2.55 |
Enterprise Value | $38.15B | $1.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Lithium Americas (LAC) trades at $3.32, down 6.74% on the day, reflecting ongoing bearish pressure. The stock shows mixed signals with a bearish technical trend but bullish oscillators like RSI at oversold levels. Fundamentally, the company remains unprofitable with negative net income of -$122.09 million in 2025, though it maintains a low P/B ratio of 0.87. Recent news highlights construction milestones at Thacker Pass and significant government funding interest in the rare earth sector.
LAC presents a high-risk, high-reward opportunity tied to its Thacker Pass project execution. Analyst consensus is cautiously optimistic with a $6.25 price target, but near-term risks include substantial capital needs, potential equity dilution, and persistent negative cash flow from operations. The stock's outlook hinges on successful project development and lithium market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
